Amarantus Bioscience Holdings, Inc (OTCPK:AMBS) signed a letter of intent to acquire biomedical assets from SeD BioMedical Inc. on February 27, 2017. These biomedical assets are: Flavonoid Compound, Clorinated Myrectin, Praesidium and Path-way Anti-Pathogenic Solution. The transaction is subject to appropriate due diligence and the signing of definitive agreement. The transaction is expected to close in respect of each target asset with the first closing date being on or June 30, 2017 and the last closing date being February 1, 2018. Amarantus Bioscience Holdings, Inc (OTCPK:AMBS) cancelled the acquisition of biomedical assets from SeD BioMedical Inc. in the third quarter of 2017.